<DOC>
	<DOCNO>NCT01762657</DOCNO>
	<brief_summary>The purpose study determine oral Cyclosporine A oral Lansoprazole effective rendering patient exist type 1 diabetes , insulin independent . This two-arm study design evaluate safety efficacy insulin independence utilize FDA-approved oral immune tolerance agent , Cyclosporine A , FDA-approved proton-pump inhibitor , Lansoprazole . Lansoprazole proton-pump inhibitor increase gastrin level . Gastrin initially show potential increase new beta cell formation 1955 ( Zollinger RM Ellison EH . Ann Surg . 1955 ; 142 ( 4 ) :709-23 ) . Studies immune tolerance agent , Cyclosporine A , previously demonstrate among recently diagnose type 1 diabetes patient , insulin independence achieve many 67.5 % patient within 7 week therapy ( Bougneres PF et al . N Engl J Med . 1988:17 ; 318 ( 11 ) :663-70 ) . Cyclosporine A protected remain beta cell autoimmune attack , time , limited beta cell regeneration , insulin ultimately required patient . Therefore , study proposes usage Cyclosporine A beta regeneration agent . Follow-up study 13 year among 285 type 1 patient utilizing Cyclosporine A 20 month , demonstrate renal side effect ( Assan R. et al . Diabetes Metab Res Rev . 2002 ; 18 ( 6 ) :464-72 ) . Human clinical trial gastrin epidermal growth factor demonstrate reduction daily insulin requirement much 75 % within 3 month follow four week therapy among exist type 1 diabetes patient ( Transition Therapeutics , March 5 , 2007 http : //www.transitiontherapeutics.com/media/archive.php Accessed January 1 , 2013 ) . Lack ability sustain result likely due ongoing autoimmune attack new beta cell generate therapy . Gastrin alone show induce beta cell neogenesis human pancreatic ductal tissue without epidermal growth factor vitro study ( Suarez-Pinzon WL et al . JCEM . 2005 ; 90 ( 6 ) :3401-3409 ) . Type 1 diabetes autoimmune disease . Despite evidence many different immune tolerance agent successfully reverse diabetes rodent type 1 model , none successful sustain insulin independence man ( Ablamunits V et al . Ann NY Acad Sci . 2007 ; 1103:19-32 ) . The distinction complexity islet man far different rodent ( Levetan CS Pierce SM . Endocr Pract . 2012 Nov 27:1-36 Epub ahead print ) . We hypothesize man , immune tolerance agent beta regeneration agent require sustain insulin independence . Based upon proton-pump inhibitor show increase plasma gastrin level 10-fold , clinical trial utilizes oral proton-pump inhibitor , Lansoprazole . This study determine safety efficacy Cyclosporine A use without Lansoprazole determine impact insulin independence among patient exist type 1 diabetes . Cyclosporine A utilized protect new beta cell form Lansoprazole . The combination two therapy may render reduction insulin requirement great impact sustain insulin independence previously report Cyclosporine A gastrin alone among type 1 patients.A This 52-week study consist two treatment arm design assess safety efficacy achieve insulin independence use : - Oral Lansoprazole/Oral Cyclosporine A - Oral Placebo/Oral Placebo It hypothesize combination oral Cyclosporine A oral Lansoprazole safely render significantly patient exist type 1 diabetes , insulin independent may serve novel innovative treatment approach patient type 1 diabetes utilize two FDA-approved therapy .</brief_summary>
	<brief_title>The Insulin Independence Trial ( IIT ) Evaluating Safety Efficacy Oral Cyclosporine Oral Lansoprazole Insulin Independence Among Patients With Existing Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>1 . They male female , 860 year age 2 . They history onset type 1 Diabetes Mellitus 20 year age ; documentation autoimmunity test pancreas include one follow test Isletcell autoantibodies 512 ( ICA512 ) /islet antigen2 ( IA2 ) , Glutamic Acid Decarboxylase ( GAD ) autoantibody , Insulin autoantibody ( subject insulin 2 week , ICA512/IA2 GAD must positive ) 3 . They Cpeptide great equal 0.6 ng/mL ( 0.2 nmol/L ) 4 . They Hemoglobin A1C level less 9 % 5 . They able willing participate study , evidence provide write informed consent 6 . Females must postmenopausal ( least 1 year without spontaneous menses ) surgically sterile ( tubal ligation hysterectomy least 6 month prior enrollment ) , negative pregnancy test practice acceptable contraception [ e.g. , oral , intramuscular , implanted hormonal contraception , sexual partner nonreversed vasectomy ( azoospermia 2 test ) , 2 barrier method ( e.g. , condom , diaphragm , spermicide ) , intrauterine device ] . Females childbearing potential must undergo pregnancy test within 24 hour prior administration first dose study drug . 1 . Prior administration immune tolerance therapy immune tolerance clinical trial type 1 diabetes 2 . Participation type therapeutic drug vaccine clinical trial within last 12 week randomization Study Day 0 3 . Any medical condition , opinion investigator , would interfere safe completion trial 4 . Pregnant female lactate female intend provide breast milk baby study 5 . Current therapy GLP1 receptor agonist ( e.g. , exenatide pramlintide ) , agent might stimulate pancreatic beta cell regeneration insulin secretion 6 . Current treatment oral antidiabetic agent 7 . Evidence active latent tuberculosis 8 . Vaccination live virus organism within 8 week randomization continue week 52 study Influenza vaccination kill virus , include booster vaccination , within 4 week dose cycle Vaccination antigens kill organism within 8 week dose cycle 9 . Systolic diastolic blood pressure &gt; 150 mmHg 90 mmHg , respectively , measure appropriately size cuff ; 10 . A body mass index ( BMI ) &gt; 28 kg/m2 11 . Worsening retinopathy , angina , congestive heart failure 12 . A history presence acute chronic pancreatitis 13 . A history presence illness , disease , condition could impact patient safety evaluability drug effect , Investigator 's opinion 14 . An episode severe hypoglycemia ( defined change mental status require assistance ) prior 30 day 15 . An episode diabetic ketoacidosis prior 6 month 16 . Received new hypoglycemic medication within past 3 month 17 . An aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , total bilirubin level &gt; 2 time upper limit normal ( ULN ) 18 . A blood urea nitrogen ( BUN ) level &gt; 50 mg/dL serum creatinine level &gt; 1.4 mg/dL 19 . A serum amylase level &gt; 1.5 time ULN serum lipase level &gt; 2 time ULN 20 . A history substance abuse dependence past year define Diagnostic Statistical Manual Mental Disorders , ( DSM V ) criterion</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>Insulin Independence</keyword>
	<keyword>Beta Regeneration</keyword>
	<keyword>Immune Tolerance Agent</keyword>
	<keyword>Lanzoprazole</keyword>
	<keyword>Cyclosporine</keyword>
</DOC>